I Voloshyna1, J Mounessa1, S E Carsons1, A B Reiss1. 1. Winthrop Research Institute and Division of Rheumatology, Allergy and Immunology, Department of Medicine, Winthrop-University Hospital, Mineola, NY, USA.
Abstract
BACKGROUND: Leptin, an adipocyte-derived circulating cytokine that signals nutritional status, may play a role in the development of psoriasis and its associated systemic diseases. Patients with psoriasis have significantly decreased serum leptin levels compared with controls. AIM: To investigate the effect of two commonly used anti-psoriatic biologic drugs, adalimumab and ustekinumab, on leptin and leptin receptor expression in human macrophages. METHODS: THP-1 differentiated macrophages were cultured under the following conditions: (i) untreated control, (ii) adalimumab 5 μg/mL, (iii) ustekinumab 1 μg/mL and (iv) ustekinumab 5 μg/mL. Expression of leptin and leptin receptors were measured using real-time quantitative PCR and immunoblotting techniques. RESULTS: The presence of either adalimumab or ustekinumab in growth medium significantly upregulated expression of leptin receptor in THP-1 human macrophages to 1.98 ± 0.47 and 2.09 ± 0.24, respectively (n = 3, P < 0.01) vs. 1.12 ± 0.19 for untreated control cells. However, only ustekinumab at a concentration of 5 μg/mL augmented expression of leptin to 1.99 ± 0.56 (n = 3, P < 0.01) vs. control untreated cells. CONCLUSIONS: Enhanced leptin and leptin receptor expression in macrophages exposed to therapeutic levels of ustekinumab suggest a novel immunomodulatory mechanism for this biologic drug. Further mechanistic studies may yield targeted treatment using the leptin pathway, which could reduce the common obesity-related complications of psoriasis while alleviating symptoms and improving prognosis.
BACKGROUND:Leptin, an adipocyte-derived circulating cytokine that signals nutritional status, may play a role in the development of psoriasis and its associated systemic diseases. Patients with psoriasis have significantly decreased serum leptin levels compared with controls. AIM: To investigate the effect of two commonly used anti-psoriatic biologic drugs, adalimumab and ustekinumab, on leptin and leptin receptor expression in human macrophages. METHODS:THP-1 differentiated macrophages were cultured under the following conditions: (i) untreated control, (ii) adalimumab 5 μg/mL, (iii) ustekinumab 1 μg/mL and (iv) ustekinumab 5 μg/mL. Expression of leptin and leptin receptors were measured using real-time quantitative PCR and immunoblotting techniques. RESULTS: The presence of either adalimumab or ustekinumab in growth medium significantly upregulated expression of leptin receptor in THP-1human macrophages to 1.98 ± 0.47 and 2.09 ± 0.24, respectively (n = 3, P < 0.01) vs. 1.12 ± 0.19 for untreated control cells. However, only ustekinumab at a concentration of 5 μg/mL augmented expression of leptin to 1.99 ± 0.56 (n = 3, P < 0.01) vs. control untreated cells. CONCLUSIONS: Enhanced leptin and leptin receptor expression in macrophages exposed to therapeutic levels of ustekinumab suggest a novel immunomodulatory mechanism for this biologic drug. Further mechanistic studies may yield targeted treatment using the leptin pathway, which could reduce the common obesity-related complications of psoriasis while alleviating symptoms and improving prognosis.
Authors: Nicholas J Wilson; Katia Boniface; Jason R Chan; Brent S McKenzie; Wendy M Blumenschein; Jeanine D Mattson; Beth Basham; Kathleen Smith; Taiying Chen; Franck Morel; Jean-Claude Lecron; Robert A Kastelein; Daniel J Cua; Terrill K McClanahan; Edward P Bowman; Rene de Waal Malefyt Journal: Nat Immunol Date: 2007-08-05 Impact factor: 25.606
Authors: Mark Lebwohl; Newman Yeilding; Philippe Szapary; Yuhua Wang; Shu Li; Yaowei Zhu; Kristian Reich; Richard G Langley; Kim A Papp Journal: J Am Acad Dermatol Date: 2010-10 Impact factor: 11.527
Authors: C L M Krieckaert; S C Nair; M T Nurmohamed; C J J van Dongen; W F Lems; F P J G Lafeber; J W J Bijlsma; H Koffijberg; G Wolbink; P M J Welsing Journal: Ann Rheum Dis Date: 2013-11-21 Impact factor: 19.103
Authors: Yvonne Baumer; Qimin Ng; Gregory E Sanda; Amit K Dey; Heather L Teague; Alexander V Sorokin; Pradeep K Dagur; Joanna I Silverman; Charlotte L Harrington; Justin A Rodante; Shawn M Rose; Nevin J Varghese; Agastya D Belur; Aditya Goyal; Joel M Gelfand; Danielle A Springer; Christopher Ke Bleck; Crystal L Thomas; Zu-Xi Yu; Mårten Cg Winge; Howard S Kruth; M Peter Marinkovich; Aditya A Joshi; Martin P Playford; Nehal N Mehta Journal: JCI Insight Date: 2018-01-11
Authors: Di Yan; Andrew Blauvelt; Amit K Dey; Rachel S Golpanian; Samuel T Hwang; Nehal N Mehta; Bridget Myers; Zhen-Rui Shi; Gil Yosipovitch; Stacie Bell; Wilson Liao Journal: J Invest Dermatol Date: 2021-04-19 Impact factor: 7.590
Authors: Vera Francisco; Jesús Pino; Victor Campos-Cabaleiro; Clara Ruiz-Fernández; Antonio Mera; Miguel A Gonzalez-Gay; Rodolfo Gómez; Oreste Gualillo Journal: Front Physiol Date: 2018-06-01 Impact factor: 4.566
Authors: Beniamin Oskar Grabarek; Tomasz Kasela; Iwona Adwent; Barbara Zawidlak-Węgrzyńska; Ryszard Brus Journal: Int J Mol Sci Date: 2021-02-05 Impact factor: 5.923